Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not always the way it works...I wouldn't use the word "investors" (in a penny stock?) but those who find the company sliding down often get caught holding too long, it's hard to put a proper stop loss in a penny stock.
So we become Bagholders.
Other options are to hold on for good or bad, get all out and move to the next one, average down or sell part of you holdings in thirds or halves...
At this point the bagholders are typically those who held on because they fell in love with the stock and keep on convincing themselves and anyone else who will listen that it's a great longterm investment.
So that's why I'm more interested in Todos as it is now rather that what it could be.
There are thousands of Companies languishing with half developed products that have run out of money in a dead sector.
Actually what I was asking was answered by DDDrey but thanks. I'm not so much interested in promises and plans down the road but rather what is actually happening now
Okay Leslunier, thanks , I will do that
Thanks again DDD
I didn't think so
Are there other or any revenue streams besides Tollovid ($1,000,000 so far)?
What clinical trials are we in now?
What is the testing numbers? Do we know?
Another slow day for the shareprice, it seems that the shares are just trading back and forth between 5 or six broker/dealers, whether they're flipping or we're being covered by HFT's.
At least the stock closed reasonably solid at .018.
We need some real news with some kind of benchmark made or a promise come true. I wouldn't hold my breath on EUA, that is hard to come by unless your name is Pfizer or Moderna
"TOMDF getting closer to some major network coverage. Spoke with two financials arms of MSM this weekend. Long COVID is on their minds big time with Q3 GDP looming, and the JJ Watt post-COVID story on the table as well." GC On Twitter
Whassappenin...light trading today, 2 trades so far
Thanks for asking, Like TODOS aspirin has a natural background,, the active ingredient in aspirin, acetylsalicylic acid works by inhibiting several different chemical processes within the body, including the natural physiological processes causing pain and inflammation.....and interestingly enough Broccoli, cauliflower, cucumber, mushrooms, radishes, spinach, and zucchini all contain high amounts of salicylates. Vegetables from the nightshade family, like eggplant and peppers, also contain salicylates.....
Well spoken!
Monday Big BIG, HUGE money coming into TOMDF. Could be the next $15B Moderna I hear TOMDF is just missing a bunch of products, features, security and users. Oh and a real exchange that has things like SEC compliance.
Chart looking like its almost reached bottom
But maybe that is just institutional investors money propping it up...or maybe daytraders....or HFT's? ...
Who knows anyway.... can be tricky to tell.
One thing is for sure.....
VALUE OF 3CL PROTEASE INHIBITOR SUPPLEMENTATION 1 The Value of 3CL Protease Inhibitor Supplementation in Long Haul Syndrome Patients?
" Thus, based upon the research available to date, there is a strong indication that introducing a regimen of supplementation with a 3CL protease inhibitor early in the symptomatic phase increases the chances of resolving COVID-19 symptoms.
Additional research is needed to better understand the correlation of outcome with
early intervention."
" Over 80% of all respondents found improvement in both COVID and LHS symptoms after taking Tollovid. Results are significant and demonstrate a self-reported benefit to using the supplement for a 5-day course."
" In fact, the majority of LHS patients report that food supplementation is their primary mode to achieve symptom relief. In this publication, we report data from over 100 Acute COVID and LHS patients on the potential benefits of Tollovid, a 3CL protease inhibitor cleanse supplement.
Based upon this analysis, further investigation is warranted in a controlled, prospective clinical trial setting."
https://www.researchgate.net/publication/362791461_VALUE_OF_3CL_PROTEASE_INHIBITOR_SUPPLEMENTATION_1_The_Value_of_3CL_Protease_Inhibitor_Supplementation_in_Long_Haul_Syndrome_Patients_The_Value_of_3CL_Protease_Inhibitor_Supplementation_in_Long_Haul_Sy
A wise man once said " reverse splits never work out I hear." and even GC said we won't do it until the time is right, am I right?
Yet the stock struggles. It's my belief that the shareprice is failing now because there is major disappointment and reluctance to put money into (I wouldn't call it 'investing') the stock. I mean why would anyone buy a struggling penny stock now, when it is preparing to do a reverse split ?
There was an AGM last week but so far I haven't heard if there are any concrete revenue generators or clinical trials active at this point. Promises yes...lots... but I'd like to see something more substantial.
Some would say that things are in the works , do some dd, check the news releases....and I have. And believe it or no it makes me even more unsure.
Appreciate some feedback here , especially from a new poster.
Records are being broken
Tomdf approaching a new 52 week low during trading. Is $0.01 in play next week? hope not...with an r/s coming that might not be good
Day Range Friday : .0196-.015
52 Week Range: .644 - .0103...nice upside potential ?
Are there other or any revenue streams besides Tollovid ($1,000,000 so far)?
What clinical trials are we in now?
What is the testing numbers? Do we know?
CEO on Twitter - It sure is nice that GC gets it done and has a good presence on Twitter, I wonder if TOMDF follow this board.
Todos have been good enough to keep us posted with their plans going forward. Being a relatively new shareholder I think that it's getting a bit confusing with all of the plans the company has versus what has actually already transpired. After a while promised don't make the shareprice stronger since a lot of old news and hopes are already built-in to the shareprice.
I'm getting confused as to what is actually really being done NOW ....we have Tollovid now as a online revenue stream, testing is confusing in that some tests are approved and being used somewhere and clinics are planned , but is testing bringing in revenue now?
And that's another thing. What is actually in clinical testing now as we speak?
Are there other revenue streams that are actually bringing in money Now?
I think most of the action/volume on the shareprice looks like micro penny flippers and HFT's so the shareprice is vulnerable....Press Releases with future plans no longer move it or strengthen it.
I have read the news but still confused.
So the question is are there other or any revenue streams besides Tollovid?
And are we currently actively in a clinical trial?
Board sets new record....1 member has had 44 posts removed from the TOMDF board in 13 days. That's 33.8% of their posts removed, (soon to be 45 or 34.6% of them)
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM
WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
05/12/2022 12:30 PM
WARREN, N.J. , May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
05/11/2022 12:30 PM
WARREN, N.J. , May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial
Medium volume yesterday. Big things coming into TOMDF. Could be the next Pfizer.
Todos is just missing a bunch of proven products, finished raises, and investors.
Needs a real exchange that has more compliance regulations.
Chart looking like its reached bottom a few times, just needs one of the promises to become realized then we may see a pop.
Red earlier you posted an interesting post, "Was there a question about these two analysts that followed...." who were you quoting in the last 6 paragraphs of the post?
JFB sorry you stated that "I especially like the option with the new share structure to bring 100% of 3CL Pharma/Sciences back under Todos ownership."
Where was that written?
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
September 30, 2022 09:59 ET | Source: Todos Medical Ltd.
https://www.globenewswire.com/news-release/2022/09/30/2526085/0/en/Todos-Medical-Receives-Two-Notices-of-Allowance-from-USPTO-for-AI-Based-TBIA-Pan-Cancer-Blood-Diagnostics-Platform.html
Proposal 4. The reauthorization of the Company’s Board of Directors to effect a reverse split of the Company’s ordinary shares, such that the Board of Directors may effect a reverse split of the Company’s entire share capital share at a ratio within the range from 1-for-2 up to 1-for-500, provided that the Company shall not effect reverse share splits that, in the aggregate, exceed 1-for 500 was approved by the stockholders by the votes set forth in the table below:
For........ ......... Against.......... .... Abstain
261,232,412/.... 44,435,499/.... 4,324,681
So what happened at the TODOS AGM....500:1 split coming?
I just checked the OTCQB and they have many stocks that are over 2 or 3 bucks and more that trade higher....what's the big deal?
If you say it's because institutional investors would want that....not true, many are quite happy if the shareprice is 50 cents or more...lots of room for them to hedge (short) so let's just wait
why do TOMDF have to R/S if they can just grow the price with time and merit. The listing and Financial requirements on the NasDaq are much more stringent too , I would think?
Quinine likely the worst example here since it has awful side effects, can you not find a better example like Penicillin or Nitric Oxide maybe ....see Link
https://investorshub.advfn.com/Nitric-Oxide-generated-and-TCM-Related-Health-Stocks-41481
Beyond Air® To Participate in Three Upcoming Investor Conferences
LifeSci Partners HealthTech Symposium – September 20-21, 2022
Title: Beyond Air (XAIR) Fireside Chat
Date & Time: Wednesday, September 21, 2022, at 12:00 – 12:25pm ET
Moderator: Corey Davis, Ph.D., LifeSci Advisors, LLC
Participant: Steve Lisi, Chairman & CEO, Beyond Air
Location: Virtual
Webcast Link: Link
Ladenburg Thalmann Healthcare Conference – September 29, 2022
Title: Beyond Air (XAIR) Company Presentation
Date & Time: Thursday, September 29, 2022, at 1:30pm – 1:55pm ET
Presenter: Steve Lisi, Chairman & CEO, Beyond Air
Location: Sofitel New York City
Webcast Link: Link
Roth Inaugural Healthcare Opportunities Conference – October 6, 2022
Title: Beyond Air (XAIR) Company Presentation
Date & Time: Thursday, October 6, 2022, (Time - TBD)
Presenter: Steve Lisi, Chairman & CEO, Beyond Air
Location: The Yale Club, New York City
Webcast Link: TBD
https://stockhouse.com/news/press-releases/2022/09/16/beyond-air-xae-to-participate-in-three-upcoming-investor-conferences
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN. https://www.beyondair.net/news-and-events/press-releases/detail/153/beyond-air-provides-regulatory-update-for-lungfit-ph
How is nitric oxide stored in the human body?
Nitric oxide does not usually exist in its free form in the body due to its unstable nature but reacts with other molecules to form more stable products.
In the blood, nitric oxide has a very short half-life and rapidly oxidises to nitrite. It is then further oxidised with oxyhaemoglobin to produce nitrate. Nitric oxide also reacts directly with oxyhaemoglobin to produce methhaemoglobin and nitrate.
Reactions with cysteine residues in proteins lead to formation of nitrosylated products. Because of its high affinity to sulfhydryl groups (thiols), S-nitrosothiols (RSNOs) are the most common nitrosylated product in plasma.
Nitrate is the main storage form of nitric oxide. It is very stable when compared with other storage forms such as nitrites and RSNOs, which are important carriers and donor molecules of nitric
Beyond Air (XAIR) Investor Presentation - Slideshow
The following slide deck was published by Beyond Air, Inc. in conjunction with this event.
For further details see:
https://static.seekingalpha.com/uploads/sa_presentations/694/87694/original.pdf
Beyond Air (XAIR) Investor Presentation - Slideshow
The following slide deck was published by Beyond Air, Inc. in conjunction with this event.
For further details see:
https://static.seekingalpha.com/uploads/sa_presentations/694/87694/original.pdf
There would not be a premium , that's not how it works. They would set a price based on the current TOMDF shareprice and pay in a multiple of so many shares of Tomdf for 1 share of Pfizer or Moderna .
For example if the buyer had a current sp of $1 and TOMDF was trading at .02 then you would get 1 share of Bigpharma for 50 TOMDF... there is no premium, no gain for the shareholder
You state: "Bottom line, based on doing my own due diligence (DD), I have no problem, waiting for NSAV to mature to some much higher and significant levels of growth."
What if Crypto continues it's struggle or do you feel it will bounce as well?
G1 Execution Services, LLC (aka ETRF) is the one at the bid with 2,914,272 shares at .0169
TOMDF struggling a bit today on relatively low volume...anyone heard from GC lately
Some studies of drugs from plants
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659925/
Supplementary Material
Lists of registered traditional Chinese medicine studies on coronavirus disease 2019 (COVID-19)
No Identifier Date of Registration Applicant's institution Study Title Status*
1 NCT04285190 2020/1/26 Tasly Pharmaceuticals, Inc. The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 1
2 ChiCTR2000029381 2020/1/27 The First Affiliated Hospital of Guangzhou Medical University A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19) 1
3 ChiCTR2000029400 2020/1/29 China Academy of Chinese Medical Sciences Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) 2
4 ChiCTR2000029418 2020/1/30 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial 2
5 ChiCTR2000029430 2020/2/1 Hubei Integrated Hospital of Traditional Chinese and Western Medicine Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19) 1
6 ChiCTR2000029432 2020/2/1 The First Afflicated Hospital of Guangzhou University of Chinese Medicine A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) 1
7 ChiCTR2000029433 2020/2/1 Hebei Yiling Hospital, Renmin Hospital of Wuhan University A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19) 3
8 ChiCTR2000029434 2020/2/1 Hebei Yiling Hospital, Renmin Hospital of Wuhan University A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of novel coronavirus pneumonia (COVID-19) 3
9 ChiCTR2000029435 2020/2/1 Wuhan 1st Hospital Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population 1
10 ChiCTR2000029436 2020/2/1 The First Hospital of He'nan University of Chinese Medicine A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) 1
11 ChiCTR2000029437 2020/2/1 Hubei Provincial Integrated Hospital of traditional Chinese and Western Medicine A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19) 1
12 ChiCTR2000029438 2020/2/1 Beijing hospital of Traditional Chinese medicine A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 1
13 ChiCTR2000029439 2020/2/1 Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University Combination of traditional chinese medicne and western medicine in the treatment of common type 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 1
14 ChiCTR2000029460 2020/2/2 Xinhua affiliated hospital, Hubei University of Chinese Medicine The effect of shadowboxing for pulmonary function and quality of life in patients with 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) in rehabilitation period 1
15 ChiCTR2000029461 2020/2/2 Xinhua affiliated hospital, Hubei University of Chinese Medicine A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) 1
16 ChiCTR2000029462 2020/2/2 The First Affiliated Hospital of He'nan University of Chinese Medicine Study for clinical characteristics and distribution of TCM syndrome of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 1
17 ChiCTR2000029479 2020/2/2 Hospital of Chengdu University of Traditional Chinese Medicine Research for Traditional Chinese Medicine Technology Prevention and Control of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in the Community Population 3
18 ChiCTR2000029487 2020/2/2 Wuhan Hospital of Integrated Traditional Chinese and Western Medicine Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Children 1
19 ChiCTR2000029493 2020/2/2 Xinhua affiliated hospital, Hubei University of Chinese Medicine Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Convalescent Period: a Randomized Controlled Trial 1
20 ChiCTR2000029495 2020/2/2 Xinhua Affiliated Hospital, Hubei University of Chinese Medicine Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Convalescent Period 1
21 ChiCTR2000029517 2020/2/3 Zhejiang Chinese Medical University Chinese medicine prevention and treatment program for suspected 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a perspective, double-blind, placebo, randomised controlled trial 2
22 ChiCTR2000029518 2020/2/3 Zhejiang Chinese Medical University Chinese medicine prevention and treatment program for 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a perspective, double-blind, placebo, randomised controlled trial 2
23 ChiCTR2000029549 2020/2/4 Hospital of Chengdu University of Traditional Chinese Medicine Recommendations of Integrated Traditional Chinese and Western Medicine for 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) 2
24 ChiCTR2000029558 2020/2/4 Hospital of Chengdu University of Traditional Chinese Medicine Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of 2019-nCoV Pneumonia (Novel Coronavirus Pneumonia, NCP) in Sichuan Province 2
25 ChiCTR2000029578 2020/2/5 Zhejiang Chinese Medical University Chinese medicine prevention and treatment program for 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP): a perspective, sing-arm trial 2
26 ChiCTR2000029589 2020/2/5 Beijing hospital of Traditional Chinese Medicine An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 2
27 NCT04251871 2020/2/5 "The Fifth Medical Center, General Hospital of PLA
Beijing, Beijing, China" Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection 2
28 ChiCTR2000029601 2020/2/6 Hubei Provincial Hospital of TCM Community based prevention and control for Chinese medicine in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) in the isolate suspected and confirmed population 2
29 ChiCTR2000029602 2020/2/6 Hubei Provincial Hospital of TCM Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population 2
30 ChiCTR2000029605 2020/2/7 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 2
31 ChiCTR2000029624 2020/2/7 Shanghai Public Health Clinical Center A real world study for traditional Chinese Medicine in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 1
32 ChiCTR2000029628 2020/2/7 Guangdong Provincial Hospital of Chinese Medicine A clinical observational study for Xin-Guan-2 formula in the treatment of suspected 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 1
33 ChiCTR2000029637 2020/2/8 Guangdong Provincial Hospital of Chinese Medicine An observational study for Xin-Guan-1 formula in the treatment of 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) 1
34 ChiCTR2000029728 2020/2/10 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology A Retrospective Study for Preventive Medication in Tongji Hospital during the epidemic of 2019-nCoV Pneumonia (novel coronavirus pneumonia, NCP) 1
35 ChiCTR2000029747 2020/2/11 The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19) 2
36 ChiCTR2000029751 2020/2/12 The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) 2
37 ChiCTR2000029755 2020/2/12 Institutional Review Board, Tongji Hospital, Tongji Medical College A randomized, open, parallel-controlled trial for the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19) 2
38 ChiCTR2000029756 2020/2/12 Renmin Hospital of Wuhan University Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19) 2
39 ChiCTR2000029763 2020/2/12 China Academy of Chinese Medical Sciences The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial 2
40 ChiCTR2000029769 2020/2/13 Taizhou Hospital of Zhejiang Province Babaodan Capsule used for the adjuvant treatment of Severe novel coronavirus pneumonia (COVID-19) 1
41 ChiCTR2000029777 2020/2/13 Huangshi Hospital of Traditional Chinese Medicine A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy 2
42 ChiCTR2000029778 2020/2/13 Shuguang Hospital Affiliated to Shanghai University of TCM. Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19) 2
43 ChiCTR2000029780 2020/2/13 Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19) 2
44 ChiCTR2000029781 2020/2/13 Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19) 2
45 ChiCTR2000029788 2020/2/13 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial 1
46 ChiCTR2000029789 2020/2/13 He'nan University of Chinese Medicine Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19) 2
47 ChiCTR2000029790 2020/2/13 Shanghai Pulmonary Hospital Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) 2
48 ChiCTR2000029813 2020/2/14 Shanghai Public Health Clinical Center Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19) 2
49 ChiCTR2000029814 2020/2/14 Children's Hospital of Fudan University Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19) 2
50 ChiCTR2000029819 2020/2/14 Sir Run Run Show Hospital, School of Medicine, Zhejiang University Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients 2
51 ChiCTR2000029821 2020/2/14 Deyang integrative medicine hospital Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation 1
52 ChiCTR2000029822 2020/2/14 Nanjing Second Hospital A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection 2
53 ChiCTR2000029855 2020/2/15 The First Affiliated Hospital of Medical College of Zhejiang University A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) 2
54 ChiCTR2000029869 2020/2/15 Huangshi Hospital of Traditional Chinese Medicine A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy 1
55 ChiCTR2000029896 2020/2/16 Affiliated Hospital of Changchun University of traditional Chinese Medicine Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) 2
56 ChiCTR2000029941 2020/2/17 Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19) 1
57 ChiCTR2000029947 2020/2/17 Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19) 1
58 ChiCTR2000029954 2020/2/17 Hubei Hospital of Traditional Chinese Medicine Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial 2
59 ChiCTR2000029956 2020/2/17 Hospital of Chengdu University of Traditional Chinese Medicine Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19) 1
60 ChiCTR2000029960 2020/2/17 The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province 1
61 ChiCTR2000029976 2020/2/18 Shanghai University of Traditional Chinese Medicine The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19) 2
62 ChiCTR2000029978 2020/2/18 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19) 1
63 ChiCTR2000029991 2020/2/18 The First Affiliated Hospital of Nanchang University A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19) 2
64 ChiCTR2000030386 2020/2/18 Hu'nan University of Chinese Medicine Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19) 1
65 ChiCTR2000029993 2020/2/19 The First Affiliated Hospital of Guangzhou Medical University A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19) 2
66 ChiCTR2000029994 2020/2/19 Huangshi Hospital of TCM/Faculty of Rehabilitation Medicine, Shanghai University of Chinese Medicine Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial 1
67 ChiCTR2000030000 2020/2/19 Nanchang Ninth Hospital An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19) 2
68 ChiCTR2000030003 2020/2/19 Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19) 1
69 NCT04275388 2020/2/19 Jiangxi Qingfeng Pharmaceutical Co. Ltd. Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia 1
70 ChiCTR2000030022 2020/2/20 First Affiliated Hospital of Anhui Medical University A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19) 1
71 ChiCTR2000030027 2020/2/20 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing China Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial 2
72 NCT04278963 2020/2/20 China Academy of Chinese Medical Sciences Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 4
73 NCT04279197 2020/2/21 ShuGuang Hospital Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu 2
74 ChiCTR2000030033 2020/2/21 The First Affiliated Hospital of Guangzhou Medical University A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19) 1
75 ChiCTR2000030034 2020/2/21 Tongde Hospital of Zhejiang Province Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial 2
76 ChiCTR2000030043 2020/2/21 Peking University Third Hospital Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial 1
77 ChiCTR2000030117 2020/2/23 Jiangxi Qingfeng Pharmaceutical Co., Ltd. A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19) 2
78 ChiCTR2000030163 2020/2/24 Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of TCM A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) 1
79 ChiCTR2000030166 2020/2/24 The 5th Medical Center Chinese PLA General Hospital Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19) 1
80 ChiCTR2000030188 2020/2/24 Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19) 2
81 ChiCTR2000030215 2020/2/25 The First Affiliated Hospital of Nanchang University Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19) 1
82 ChiCTR2000030218 2020/2/25 Fifth People's Hospital of Ganzhou Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19) 2
83 ChiCTR2000030219 2020/2/25 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19) 2
84 ChiCTR2000030225 2020/2/25 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19) 1
85 ChiCTR2000030255 2020/2/26 Shanghai University of Traditional Chinese Medicine Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome 1
86 ChiCTR2000030288 2020/2/27 China Academy of Chinese Medical Sciences Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial 2
87 ChiCTR2000030305 2020/2/28 The Fourth Affiliated Hospital of Zhejiang University School of Medicine Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19) 1
88 ChiCTR2000030314 2020/2/28 Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19) 1
89 ChiCTR2000030315 2020/2/28 Affiliated Hospital of Changchun University of traditional Chinese Medicine Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) 2
90 ChiCTR2000030322 2020/2/28 Xinyang Central Hospital Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients 2
91 ChiCTR2000030324 2020/2/28 Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19) 1
92 ChiCTR2000030382 2020/2/29 Hubei Provincial Hospital of TCM Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet 2
93 ChiCTR2000030388 2020/3/1 Jingzhou First People's Hospital Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19) 2
94 ChiCTR2000030389 2020/3/1 Hubei Provincial Hospital of TCM A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19) 2
95 ChiCTR2000030418 2020/3/1 The First Affiliated Hospital of Fujian Medical University Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19) 2
96 ChiCTR2000030420 2020/3/1 Institute of Integrative Medicine of Dalian Medical University A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform 1
97 ChiCTR2000030432 2020/3/1 The First Affiliated Hospital of Fujian Medical University Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic 1
98 ChiCTR2000030433 2020/3/1 The First Affiliated Hospital of Fujian Medical University Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19) 1
99 ChiCTR2000030467 2020/3/2 Dalian Medical University A Randomized Controlled Trial for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform 1
100 ChiCTR2000030468 2020/3/2 Affiliated Hospital of Shandong University of Traditional Chinese Medicine Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation 2
101 ChiCTR2000030469 2020/3/2 Shuguang Hospital Affiliated to Shanghai University of TCM A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19) 2
102 NCT04291053 2020/3/2 Tongji Hospital The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19 1
103 ChiCTR2000030476 2020/3/3 Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine Study for emotion regulation of traditional Chinese medicine assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19) 2
104 ChiCTR2000030479 2020/3/3 Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of CM Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19) 1
105 ChiCTR2000030492 2020/3/4 The First Affiliated Hospital of Hu'nan University of TCM Retrospective study for integrate Chinese and conventional medicine treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province 1
106 NCT04295551 2020/3/4 Jiangxi Qingfeng Pharmaceutical Co. Ltd. Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) 1
107 ChiCTR2000030522 2020/3/5 Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19) 2
108 ChiCTR2000030528 2020/3/5 The Second Clinical College of Guangzhou University of Chinese Medicine Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19) 1
109 ChiCTR2000030545 2020/3/6 Hubei Hospital of Traditional Chinese Medicine Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial 2
110 ChiCTR2000030597 2020/3/8 Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19) 1
111 ChiCTR2000030606 2020/3/8 Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19) 1
112 ChiCTR2000030619 2020/3/8 The First Affiliated Hospital of Bengbu Medical College A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19) 3
113 ChiCTR2000030719 2020/3/11 Wuhan Hospital of Integrated Traditional Chinese and Western Medicine A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan 2
114 ChiCTR2000030747 2020/3/13 Hubei Provincial Hospital of TCM A prospective cohort study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19) 2
115 ChiCTR2000030751 2020/3/13 Affilated Hospital of Inner Mongolia University for the Nationalities Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19) 1
116 ChiCTR2000030759 2020/3/13 The First Affiliated Hospital of Wenzhou Medical University Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) 1
117 NCT04306497 2020/3/13 Jiangsu Famous Medical Technology Co., Ltd. Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19. 2
118 ChiCTR2000030804 2020/3/15 Maoming People's Hospital Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial 2
119 ChiCTR2000030806 2020/3/15 Wuhan 3rd Hospital Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19) 2
120 ChiCTR2000030810 2020/3/15 Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&Western Medicine 2
121 ChiCTR2000030836 2020/3/15 Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy 1
122 ChiCTR2000030864 2020/3/16 Xiangyang 1st People's Hospital Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19) 2
123 ChiCTR2000030883 2020/3/16 Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19) 2
124 ChiCTR2000030896 2020/3/16 Zhengzhou People's Hospital Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19) 2
125 ChiCTR2000030898 2020/3/16 Affiliated Hospital of Changchun University of Traditional Chinese Medicine Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19) 2
126 ChiCTR2000030920 2020/3/17 HwaMei Hospital, University of Chinese Academy of Sciences Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence. 2
127 ChiCTR2000030923 2020/3/17 Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19) 2
128 NCT04310865 2020/3/17 China Academy of Chinese Medical Sciences Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 4
129 ChiCTR2000030933 2020/3/18 The First Affiliated Hospital of Nanchang University Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial 1
130 ChiCTR2000030936 2020/3/18 Hospital of Chengdu University of Traditional Chinese Medicine A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19) 2
131 ChiCTR2000030937 2020/3/18 the First Affiliated Hospital of Guangzhou Medical University A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen 2
132 ChiCTR2000030938 2020/3/18 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia (COVID-19) 2
133 ChiCTR2000030940 2020/3/18 Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine Study for Bai-Du Duan Fang application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19) 1
134 ChiCTR2000030962 2020/3/20 Hospital of Chengdu University of Traditional Chinese Medicine Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study 1
135 ChiCTR2000030988 2020/3/20 Guangdong Provincial Hospital of Chinese Medicine A randomized controlled trial for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) 1
136 ChiCTR2000030996 2020/3/20 Nursing Department of Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial. 2
137 ChiCTR2000031089 2020/3/22 Guangzhou Eighth People's Hospital A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19) 1
138 ChiCTR2000031203 2020/3/24 Zhengzhou People's Hospital Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19) 2
139 NCT04323332 2020/3/26 Xiyuan Hospital of China Academy of Chinese Medical Sciences Traditional Chinese Medicine for Severe COVID-19 1
140 ChiCTR2000031672 2020/4/5 Beijing University of Chinese Medicine Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19) 1
141 ChiCTR2000031888 2020/4/13 Guangzhou Eighth People's Hospital A medical records based study for ''Guangdong Pneumonia NO.1'' in the Treatment of Novel Coronavirus Pneumonia (COVID-19) 2
142 AMCTR-IPR-20000326 2020/4/14 Hunan University of Chinese Medicine Research on close contacts of novel coronavirus pneumonia with moxibustion 1
143 ChiCTR2000031955 2020/4/15 Beijing University of traditional Chinese Medicine Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine 2
144 ChiCTR2000031982 2020/4/16 The Fifth Affiliated Hospital of Sun Yat-Sen University Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people 1
145 ChiCTR2000032040 2020/4/18 Affiliated Hospital of Guangdong Medical University A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19) 2
146 ChiCTR2000032098 2020/4/19 Union Hospital Danggui Shaoyao Powder in the synergistic treatment of novel coronavirus pneumonia (COVID-19) 2
147 ChiCTR2000032165 2020/4/21 Hubei Provincial Hospital of TCM A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period 1
148 ChiCTR2000032205 2020/4/23 Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan 1st Hospital) A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia 1
149 ChiCTR2000032214 2020/4/23 Hubei Provincial Hospital of TCM Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients 1
150 ChiCTR2000032237 2020/4/23 Ezhou Hospital of traditional Chinese Medicine A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence 2
151 ChiCTR2000032313 2020/4/25 Beijing University of Chinese Medicine, Third Affiliated Hospital Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19) 1
152 ChiCTR2000032367 2020/4/26 Yueyang Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Efficacy of Liu-zi-jue in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19): a randomized controlled trial 2
153 ChiCTR2000032399 2020/4/27 Xiaogan Traditional Chinese Medicine Hospital A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19) 2
154 ChiCTR2000032412 2020/4/27 Jiangxi Qingfeng Pharmaceutical Co., Ltd./Shanghai Public Health Clinical Center A medical records based retrospective study for the effectiveness and safety of Xi-Yan-Ping injection combined with conventional protocol in the treatment of common type novel coronavirus pneumonia (COVID-19) 1
155 ChiCTR2000032461 2020/4/29 Chengdu University of Traditional Chinese Medicine A medical records based retrospective study for effect of applying individualized Chinese herbal medicine in treatment of patients with novel coronavirus pneumonia (COVID-19) 1
156 ChiCTR2000032478 2020/4/29 Institute of Basic Research for Clinical Medicine, China Academy of Chinese Medical Sciences TCM Intervention study for novel coronavirus pneumonia (COVID-19) patient during home/designate-unit isolation based on community prevention and control 2
157 ChiCTR2000032480 2020/4/29 Institute of Basic Research for Clinical Medicine, China Academy of Chinese Medical Sciences Study on data management and diagnosis-treatment mode of TCM intervention for novel coronavirus pneumonia (COVID-19) convalescence 1
158 ChiCTR2000032573 2020/5/3 The First Affiliated Hospital of Guangzhou Medical University A randomized, double-blind, controlled trial for Bu-Fei-Huo-Xue Capsule in the treatment of novel coronavirus pneumonia (COVID-19) convalescence patient with ''Fei-Pi-Qi-Xu zhen'' 1
159 ChiCTR2000032635 2020/5/4 Hubei Provincial Hospital of TCM Study for Screening of Chinese Patent Drugs in the Rehabilitation Treatment of novel coronavirus pneumonia (COVID-19) 1
160 ChiCTR2000032717 2020/5/8 Xi'an International Medical Center Hospital Efficacy and safety of high-dose vitamin C combined with traditional Chinese medicine in the treatment of moderate and severe novel coronavirus pneumonia (COVID-19) 3
Note: Status*: 1 Not yet recruiting; 2 Recruiting; 3 Completed; 4 Suspended.
If we use common sense wouldn't we have got out of this 2 or 3 years ago?
So I have a question again....I thot James got the boot a few years ago when the AltCoin market was hot. Then I got out and now I hear he's back?
Whassssappenin?
So your point JP is it's better to design/source your product from Woodchuck virus than a natural herbal product? Thanks, I guess
Another study has determined that of all current pharmaceutical products, about 73%, include ingredients derived from natural products
I don't think any big Pharma would be interested until the product has been proved , as in finish Phase 3 and maybe even 4.
I hope TOMDF take this all the way. More money in that for shareholders . A takeover could mean we get the same shareprice for our shares based on today's sp.
Where's the fun in that?